Bioreactor Market Size By Cell (Mammalian Cells, Bacterial Cells, Yeast Cells, Others), By Molecule (Monoclonal Antibodies, Vaccines, Recombinant Proteins, Stem Cells, Gene Therapy, Others), By Technology (Wave-Induced Motion SUB, Stirred SUB, Single Use Bubble Column, Other SUB), By End-Use ( R&D organizations, Biopharma Manufacturers, CMOs) Industry Analysis Report, Regional Outlook (U.S., Canada, Germany, UK, Spain, Italy, France, Netherland, Denmark, China, Japan, India, South Korea, Australia, Singapore, Brazil, Mexico, UAE, South Africa), Application Development, Price Trend, Competitive Landscape & Forecast, 2017 – 2024
Published Date: May 2017 | 100 Pages | Report ID: GMI141 Report Format: PDF
Bioreactor Market size was valued at over USD 500 million in 2016 and expects gains at over 18% by 2024.
U.S. Bioreactor Market Share, By Technology, 2016
Rising chronic diseases prevalence, and soaring biopharmaceutical investments will drive the global bioreactor market size. Growing demand for therapeutically effective vaccines, product innovation, and favorable government initiatives to improve healthcare infrastructure will further stimulate business growth.
Development of orphan drugs and personalized medicine should provide effective healthcare by improvements in diagnosis, treatment, and monitoring of chronic diseases. Increasing number of personalized medicines targeting a specific population coupled with rising number of FDA approved orphan drugs has increased bioproduction, accelerating the bioreactors demand over the forecast years.
Contract manufacturing organizations (CMOs) are expanding in terms of capabilities and capacities to meet the growing demand of the biopharmaceutical and bioprocessing industry. Increasing number of novel compounds entering the clinical trials coupled with analytical, formulation and cell line development services should keep up the industry trend. Regulatory concerns regarding single use bioreactor, limited storage capacity and vulnerability to leaching may hinder bioreactor market growth. Furthermore, large-scale disposal of plastic derivatives is a growing environmental concern restraining the business growth.
Bioreactor Market, By Cell
Mammalian cells accounted for over 75% of the bioreactor market share owing to its wide application in production of therapeutic proteins and viral vaccines. Emergence of gene therapy and tissue engineering should boost the industry growth over forecast years.
Yeast cells demand is forecast to witness over 15% CAGR over the forecast years. It manifests probiotic activity when used as single culture or combined with other probiotic strains. Increasing research for industrial scale production of probiotic yeasts will drive the industry expansion over the coming years. The associated benefits of insect cells such as ease of culture, by-product concentration, high tolerance to osmolality, and higher expression levels will prove favorable to global business growth. These factors will increase their use and revenue share in the coming years.
Bioreactor Market, By Molecule
Monoclonal antibodies generated over USD 190 million in 2016 owing to increasing application in treatment of asthma, breast cancers, rheumatoid arthritis, psoriasis, leukemia, chronic gastrointestinal inflammatory disease, and transplant rejection. Advanced bioprocess equipment that meets the specific demands for mAb production should accelerate the growth.
Stem cells should witness over 18% CAGR by 2024 due to its immense potential in diagnosis and treatment of a disease and therapeutic applications in medicine. Commercial production of human stem cells, growth factors and mediators should fuel business expansion. Other molecules are set to surpass USD 170 million by 2024. Oligonucleotides demand should increase with the growing research in molecular diagnostics field and soaring investments in genomic technologies.
Bioreactor Market, By Technology
Wave-induced motion market held more than 50% of industry revenue due to its extensive use in modern biotechnological processes. It is mainly used in laboratory and pilot scale owing to its enhanced flexibility with adequate productivity. Stirred SUBs will witness more than 18% CAGR owing to its huge demand in the biopharmaceutical industry. The ability to reduce scale-up risks and maintain clean environment throughout the production process should stimulate industry growth.
Increasing single use bioreactor market size in biopharmaceutical companies coupled with technological innovation to develop disposable alternatives will extend its utility in clinical as well as commercial scale manufacturing operations. Extensive use of hybrid bioreactor technology in effective waste management will further accelerate business expansion.
Bioreactor Market, By End-Use
Biopharmaceutical manufacturers held more than 30% of industry share in 2016. Increase in number of biopharmaceutical products in pipeline including antibodies and antibody drug conjugates (ADC) coupled with rising number of new facilities to meet the production needs should fuel business growth.
R&D organizations contributed over USD 250 million to the global industry revenue in 2016 and are projected to witness strong growth over the forecast years. Innovators and manufacturers of biopharmaceuticals and biosimilars continue to discover novel products and build pipelines involving biopharmaceuticals. Furthermore, large biopharmaceutical companies and biosimilar producers are entering strategic collaborations with new entrants to facilitate business expansion.
Bioreactor Market, By Region
U.S. bioreactor market will exceed USD 600 million estimation by 2024. Increasing number of biopharmaceutical companies responsible for bringing new medicines to patients and their collaborations with venture capital firms, academic institutions, and patients will drive the regional industry share.
Germany market contributed to over 25% of regional revenue share owing to the presence of leading industry players and increasing healthcare expenditure in this region. Favorable regulatory policies for biopharmaceutical approval and technological innovation in bioprocess equipment will propel business growth.
China bioreactor market should witness more than 19% CAGR. Growing population, increasing chronic disease prevalence, rising R&D investment, and unmet healthcare needs will stimulate industry growth. Favorable government policies to encourage biotechnological research and spurring outsourcing trend are forecast to further accelerate the industry expansion.
Competitive Market Share
Some of the major players in the bioreactor market include Sartorius, GE Healthcare, Thermo Fisher Scientific, Eppendorf, and Merck Millipore.
Key strategies adopted by the industry participants include new product launch, mergers and acquisitions, geographical expansion, strategic agreements, and collaborations. For instance, in July 2016, Sartorius acquired U.S based kSep systems, a firm engaged in the development of automated centrifugation systems used in manufacturing cell-based therapeutics, vaccines, and monoclonal antibodies. This acquisition expanded Sartorius’ bioprocessing solutions portfolio.
Bioreactor Industry Background
Bioprocessing industry has witnessed a tremendous growth over the past few years. Increasing R&D efforts to develop biopharmaceuticals have accelerated global bioreactor market growth. Adoption of tissue engineering technologies and increased production of antibodies, growth factors have stimulated overall business growth. Significant developments have taken place, especially in single-use or disposable products and other equipment, dominating small and mid-scale bioprocessing. The single-use bioreactors will increase significantly in the coming years due to development of products using single-use systems receiving approvals and progressing to commercial manufacture. Growing focus on biotechnology R&D and technological innovation will continue to drive the bioreactor industry.
What Information does this report contain?
Why Global Market Insights?Comprehensive Research
- All-inclusive coverage
- In-depth and granular data (ex: information for 8 to 15 countries, with clients open to add to this list, in each report)
- Penetrative insights & latest trends
- Offers holistic understanding of the market
- Unique methodology
- Iterative in nature to eliminate errors
- Detailed methodology, scope, assumptions and data sources available for reference
- Committed to making a positive difference for our clients
- Given the nature of this industry, we are committed to ensure that our clients get maximum return on their investment in our services
- Every purchase comes with an option to obtain additional information:
- up to 10% of the original cost
- 45-minute analyst tele-call to obtain further clarity on the market.
- Global Market Insights, Inc. strictly adheres to PCI-DSS security norms.
- Only PCI-DSS compliant payment methods used for highest level of client data security